IsoRay, Inc. (DE) (ISR): Price and Financial Metrics


IsoRay, Inc. (DE) (ISR): $0.65

0.02 (+3.74%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ISR POWR Grades


  • Sentiment is the dimension where ISR ranks best; there it ranks ahead of 93.15% of US stocks.
  • The strongest trend for ISR is in Stability, which has been heading up over the past 34 weeks.
  • ISR ranks lowest in Quality; there it ranks in the 2nd percentile.

ISR Stock Summary

  • ISR's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 9.1% of US stocks.
  • The volatility of Isoray Inc's share price is greater than that of 96.84% US stocks with at least 200 days of trading history.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ISR comes in at -64.2% -- higher than that of just 4.38% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Isoray Inc, a group of peers worth examining would be NBRV, SSD, MYGN, CCF, and LMAT.
  • ISR's SEC filings can be seen here. And to visit Isoray Inc's official web site, go to www.isoray.com.

ISR Valuation Summary

  • ISR's price/sales ratio is 9.4; this is 147.37% higher than that of the median Healthcare stock.
  • Over the past 192 months, ISR's price/sales ratio has gone down 111.2.
  • Over the past 192 months, ISR's price/sales ratio has gone down 111.2.

Below are key valuation metrics over time for ISR.

Stock Date P/S P/B P/E EV/EBIT
ISR 2021-08-31 9.4 1.3 -25.7 -7.5
ISR 2021-08-30 9.3 1.3 -25.4 -7.2
ISR 2021-08-27 9.6 1.4 -26.1 -7.9
ISR 2021-08-26 9.8 1.4 -26.7 -8.5
ISR 2021-08-25 9.9 1.4 -27.1 -8.9
ISR 2021-08-24 9.4 1.3 -25.8 -7.6

ISR Growth Metrics

  • The 5 year revenue growth rate now stands at 93.23%.
  • Its year over year revenue growth rate is now at 3.18%.
  • Its 2 year price growth rate is now at 94.77%.
Over the past 67 months, ISR's revenue has gone up $4,796,240.

The table below shows ISR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 9.622 -2.567 -3.52
2020-12-31 9.902 -2.808 -3.323
2020-09-30 9.749 -3.326 -3.354
2020-06-30 9.68 -3.641 -3.457
2020-03-31 9.325 -3.778 -3.364
2019-12-31 8.369 -4.254 -3.946

ISR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ISR has a Quality Grade of F, ranking ahead of 2.91% of graded US stocks.
  • ISR's asset turnover comes in at 0.372 -- ranking 118th of 183 Medical Equipment stocks.
  • EYE, ANIK, and LAKE are the stocks whose asset turnover ratios are most correlated with ISR.

The table below shows ISR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-03-31 0.372 0.504 -0.657
2020-12-31 0.961 0.524 -0.605
2020-09-30 1.126 0.527 -0.610
2020-06-30 1.055 0.529 -0.642
2020-03-31 0.996 0.529 -0.717
2019-12-31 0.857 0.491 -0.874

ISR Stock Price Chart Interactive Chart >

Price chart for ISR

ISR Price/Volume Stats

Current price $0.65 52-week high $2.81
Prev. close $0.63 52-week low $0.35
Day low $0.63 Volume 750,852
Day high $0.66 Avg. volume 6,202,538
50-day MA $0.67 Dividend yield N/A
200-day MA $0.98 Market Cap 91.88M

IsoRay, Inc. (DE) (ISR) Company Bio


Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. Isoray, Inc. was founded in 1998 and is headquartered in Richland, Washington.


ISR Latest News Stream


Event/Time News Detail
Loading, please wait...

ISR Latest Social Stream


Loading social stream, please wait...

View Full ISR Social Stream

Latest ISR News From Around the Web

Below are the latest news stories about Isoray Inc that investors may wish to consider to help them evaluate ISR as an investment opportunity.

Isoray Reschedules Fourth Quarter and Fiscal Year End 2021 Financial Results Conference Call to September 22, 2021 Due to Conference Provider Technical Issues

Conference Call Rescheduled for Wednesday, September 22 at 10:00 a.m. ET/7:00 a.m. PTRICHLAND, Wash., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options throughout the body, will host a rescheduled conference call to discuss its financial results for the fourth quarter and fiscal year ended June 30, 2021 on Wednesday, September 22, 2021, at 10:00 a.m. Eastern Time/7:00 a.m. Pacific

Yahoo | September 21, 2021

IsoRay (ISR) Reports Q4 Loss, Tops Revenue Estimates

IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and 3.99%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | September 21, 2021

Isoray Announces Fourth Quarter and Full-Year Fiscal Year End 2021 Financial Results

Record Full Year RevenueFiscal Fourth Quarter Revenue Increased 19% Year-Over-Year RICHLAND, Wash., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced financial results for the fiscal fourth quarter and full-year ended June 30, 2021. Revenue for the fourth quarter of fiscal 2021 grew 19% to $2.71 million versus $2.28 million in the prior ye

Yahoo | September 21, 2021

Isoray To Announce Fourth Quarter and Fiscal Year End 2021 Financial Results on September 21, 2021

Conference Call is Tuesday, September 21 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Tuesday, September 21 at 4:30 p.m. ET/1:30 p.m. PT

Intrado Digital Media | September 9, 2021

Will IsoRay (ISR) Report Negative Q4 Earnings? What You Should Know

IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | September 9, 2021

Read More 'ISR' Stories Here

ISR Price Returns

1-mo 1.25%
3-mo -20.16%
6-mo -41.96%
1-year 15.00%
3-year 16.07%
5-year -8.45%
YTD 44.44%
2020 -27.93%
2019 108.13%
2018 -24.81%
2017 -31.21%
2016 -38.30%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 2.1874 seconds.